We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
SciRhom GmbH, an advanced startup dedicated to developing transformative therapies for autoimmune diseases, today announced the appointment of their Clinical Advisory Board.
SciRhom GmbH, a developer of novel antibody therapies, announced today an increase of their seed capital by EUR 8 million. With this added investment, the company has secured a total of EUR 16 million...
SciRhom GmbH, a therapeutic antibody company, announced the development of first-in-class antibodies against iRhom2, a key modulator of several major pro-inflammatory signaling pathways ...